Palatin says King Pharma ends drug agreement on FDA concern

Sept 10 (Reuters) - Palatin Technologies Inc (PTN.A) said King Pharmaceuticals Inc (KG.N) ended its collaborative development agreement on bremelanotide used in the treatment of male erectile dysfunction and female sexual dysfunction.

Palatin said King Pharma exercised its right to terminate the deal after U.S. health regulators raised safety concerns about the efficacy of the results of the drug in early- and mid-stage trials. (Reporting by Avishek Mishra in Bangalore)